I only contact Gerald to reconcile things that con
Post# of 30028
Posted On: 11/10/2014 7:55:55 PM
Re: Daveludlow #10459
I only contact Gerald to reconcile things that concern me. This one does not. Jason's is clearly off his rocker in his latest analysis, or is trying to lure GC into making a statement as you suggested. His LymPro revenue estimates don't pass what we used to call in the Navy as the "idiot test".
His 100-to-1 RS claim is ridiculous, as the company has repeatedly stated they would NOT do that, and will delay the uplisting if necessary until the share price more accurately reflects the true underlying value of the company. Yet, Jason continues to toss out the large RS numbers. Why, when it is completely opposite of what the company has stated?
Because of this, I don't place much emphasis on Jason's latest comments, and the discrepancy between his revenue estimates and the company's don't concern me. I'll stick to the company's expectations until they update their outlook or actual revenues prove otherwise. The discrepancy may concern nervous investors, but it doesn't concern me, based on my diminished confidence in the source of the estimate.
Perhaps you can convince one of the other investors who maintain current communications with Gerald to ask for clarification. Gerald has clearly raised the bar on when and with whom he communicates, so I prefer to not bother him with unnecessary noise in order to keep my ability to communicate open so I can get responses to concerns that matter to me.
His 100-to-1 RS claim is ridiculous, as the company has repeatedly stated they would NOT do that, and will delay the uplisting if necessary until the share price more accurately reflects the true underlying value of the company. Yet, Jason continues to toss out the large RS numbers. Why, when it is completely opposite of what the company has stated?
Because of this, I don't place much emphasis on Jason's latest comments, and the discrepancy between his revenue estimates and the company's don't concern me. I'll stick to the company's expectations until they update their outlook or actual revenues prove otherwise. The discrepancy may concern nervous investors, but it doesn't concern me, based on my diminished confidence in the source of the estimate.
Perhaps you can convince one of the other investors who maintain current communications with Gerald to ask for clarification. Gerald has clearly raised the bar on when and with whom he communicates, so I prefer to not bother him with unnecessary noise in order to keep my ability to communicate open so I can get responses to concerns that matter to me.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼